Compare Cassava Sciences Inc (FLNA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs RLX Technology Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while RLX Technology Inc trades at $2.03 (market cap $2.46B). The key difference: RLX Technology Inc is far larger — about 46.3× Cassava Sciences Inc's market cap, and RLX Technology Inc pays a 4.98% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RLX | |
|---|---|---|
Market Cap | $53.14M | $2.46B |
Sector | Health | Technology |
52-Week High | $4.64 | $2.73 |
52-Week Low | $1.09 | $1.79 |
Enterprise Value | -$33.43M | $1.09B |
Dividend Yield | — | 4.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
RLX Technology trades at $2.02, up 2.02% on the day, with a bullish technical signal from moving averages. The company reported strong 2025 fundamentals with $3.62B revenue, $922M net income, and robust cash flow from operations of $1.10B. Recent Q1 2026 results showed revenue growth driven by international expansion, though EPS missed expectations for three consecutive quarters. The stock carries a P/E of 18.37 and P/S of 3.82, with no debt and significant cash reserves.
Outlook remains mixed with strong industry growth potential in vaping (projected to reach $462B by 2033) offset by recent earnings misses and a single analyst maintaining a Hold rating. Key risks include regulatory scrutiny in China and abroad, competitive pressures, and execution on international expansion. The company's debt-free balance sheet and cash-rich position provide financial flexibility amid these challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
